Moderna gains analyst confidence with FDA backing for flu vaccine and pipeline expansion.

Moderna shares jump 14% on FDA flu vaccine nod and strong pipeline outlook

Moderna's stock surged 14% to a 52-week high following an FDA advisory panel's unanimous endorsement of its flu vaccine for adults 50 and older, a key step before the August 2026 approval date. The rally also reflects optimism from Moderna's recent S...